Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies

J Dermatol. 2012 Aug;39(8):730-1. doi: 10.1111/j.1346-8138.2011.01499.x. Epub 2012 Feb 27.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dermatitis, Exfoliative / drug therapy*
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Ustekinumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Ustekinumab